36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this survey is to evaluate the effectiveness (endpoints: frequency of bone
fractures, percent change in bone density, etc.) and safety of administration of sodium
risedronate tablets 75 mg for 36 months in osteoporosis patients in daily medical practice.